Literature DB >> 18365686

Selective toxicity of ginsenoside Rg3 on multidrug resistant cells by membrane fluidity modulation.

Hyog-Young Kwon1, Eun-Hye Kim, Seung-Whan Kim, Su-Nam Kim, Jong-Dae Park, Dong-Kwon Rhee.   

Abstract

Multidrug resistance (MDR) is a major problem in cancer chemotherapy. It was previously reported that a red ginseng saponin, 20(S)-ginsenoside Rg3 could modulate MDR in vitro and extend the survival of mice implanted with ADR-resistant murine leukemia P388 cells. This study examined the cytotoxicity of Rg3 on normal and transformed cells, along with its effect on the membrane fluidity. The cytotoxicity study revealed that 120 microM of Rg3 was cytotoxic against a multidrug-resistant human fibroblast carcinoma cell line, KB V20C, but not against normal WI 38 cells in vitro. Flow cytometric analysis using rhodamine 123 as the artificial substrate showed that Rg3 promoted the accumulation of rhodamine 123 in ADR-resistant murine leukemia P388 cells in vivo. Fluorescence polarization studies using the hydrophilic fluorescent probe, DPH, and hydrophobic probe, TMA-DPH, showed that 20 microM Rg3 induced a significant increase in fluorescence anisotropy in KB V20C cells but not in the parental KB cells. These results clearly show that Rg3 decreases the membrane fluidity thereby blocking drug efflux.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18365686     DOI: 10.1007/s12272-001-1137-y

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  16 in total

1.  The distribution of saponins in vivo affects their synergy with chimeric toxins against tumours expressing human epidermal growth factor receptors in mice.

Authors:  C Bachran; A Weng; D Bachran; S B Riese; N Schellmann; M F Melzig; H Fuchs
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

Review 2.  Plant-derived triterpenoids and analogues as antitumor and anti-HIV agents.

Authors:  Reen-Yen Kuo; Keduo Qian; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2009-08-13       Impact factor: 13.423

Review 3.  Ginseng compounds: an update on their molecular mechanisms and medical applications.

Authors:  Jian-Ming Lü; Qizhi Yao; Changyi Chen
Journal:  Curr Vasc Pharmacol       Date:  2009-07       Impact factor: 2.719

4.  Pharmacology of ginsenosides: a literature review.

Authors:  Kar Wah Leung; Alice Sze-Tsai Wong
Journal:  Chin Med       Date:  2010-06-11       Impact factor: 5.455

Review 5.  Compounds from Chinese herbal medicines as reversal agents for P-glycoprotein-mediated multidrug resistance in tumours.

Authors:  C Li; B-Q Sun; X-D Gai
Journal:  Clin Transl Oncol       Date:  2014-03-19       Impact factor: 3.405

6.  Cell-type-specific regulation of raft-associated Akt signaling.

Authors:  Y Liu; G Yang; X Bu; G Liu; J Ding; P Li; W Jia
Journal:  Cell Death Dis       Date:  2011-04-14       Impact factor: 8.469

7.  In vivo early intervention and the therapeutic effects of 20(s)-ginsenoside rg3 on hypertrophic scar formation.

Authors:  Liying Cheng; Xiaoming Sun; Changmin Hu; Rong Jin; Baoshan Sun; Yaoming Shi; Wenguo Cui; Yuguang Zhang
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

Review 8.  Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein.

Authors:  Hyun-Jong Cho; In-Soo Yoon
Journal:  Evid Based Complement Alternat Med       Date:  2015-01-06       Impact factor: 2.629

9.  Ginsenoside Rp1, a Ginsenoside Derivative, Blocks Promoter Activation of iNOS and COX-2 Genes by Suppression of an IKKβ-mediated NF-кB Pathway in HEK293 Cells.

Authors:  Ting Shen; Jaehwi Lee; Myung Hwan Park; Yong Gyu Lee; Ho Sik Rho; Yi-Seong Kwak; Man Hee Rhee; Yung Chul Park; Jae Youl Cho
Journal:  J Ginseng Res       Date:  2011-06       Impact factor: 6.060

10.  Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549/DDP xenograft tumors.

Authors:  Chao Liu; Quan Gong; Ting Chen; Juan Lv; Zhiping Feng; Pengjie Liu; Zhiyong Deng
Journal:  Oncol Lett       Date:  2018-01-24       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.